Testing effectiveness (Phase 2)Study completedNCT04939662What this trial is testingOlaparib and Bevacizumab in Relapsed Small Cell Lung Cancer SubjectsWho this might be right forLung Cancer Se-Hoon Lee 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07393555What this trial is testingTreatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)Who this might be right forRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8 SWOG Cancer Research Network 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081What this trial is testingSelpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationWho this might be right forSolid TumorMedullary Thyroid Cancer Eli Lilly and Company 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT03899792What this trial is testingOral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsWho this might be right forMedullary Thyroid CancerInfantile MyofibromatosisInfantile Fibrosarcoma+2 more Eli Lilly and Company 36
Testing effectiveness (Phase 2)Looking for participantsNCT03175224What this trial is testingAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsWho this might be right forSolid TumorsAdvanced CancerRenal Cancer+15 more Apollomics Inc. 497
Testing effectiveness (Phase 2)UnknownNCT03925350What this trial is testingEfficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) MutationWho this might be right forMetastatic Melanoma California Pacific Medical Center Research Institute 41
Not applicableApproved For MarketingNCT05760586What this trial is testingExpanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade GliomaWho this might be right forLow-grade Glioma Day One Biopharmaceuticals, Inc.
Early research (Phase 1)Active Not RecruitingNCT05222802What this trial is testingEvaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)Who this might be right forGlioblastoma Multiforme Katmai Pharmaceuticals Inc. 52
Early research (Phase 1)Looking for participantsNCT07361562What this trial is testingA Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more Cogent Biosciences, Inc. 100
Testing effectiveness (Phase 2)Ended earlyNCT04161391What this trial is testingStudy of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsWho this might be right forNon Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more Turning Point Therapeutics, Inc. 41
Not applicableLooking for participantsNCT04623424What this trial is testingIntestinal Microbiota in Stem Cell Transplant Transplant AdmissionWho this might be right forStem Cell Transplant Complications Henry Ford Health System 255
Testing effectiveness (Phase 2)Looking for participantsNCT04040205What this trial is testingAbemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationWho this might be right forChondrosarcomaOsteosarcomaSoft Tissue Sarcoma Medical College of Wisconsin 44
Testing effectiveness (Phase 2)Study completedNCT03037385What this trial is testingPhase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsWho this might be right forRET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more Hoffmann-La Roche 590
Testing effectiveness (Phase 2)Looking for participantsNCT06750185What this trial is testingSafety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor BioNTech SE 248
Early research (Phase 1)Looking for participantsNCT04913285What this trial is testingEvaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsWho this might be right forSolid Tumor, AdultNon-small Cell Lung CancerMelanoma Pierre Fabre Medicament 400
Early research (Phase 1)Ended earlyNCT05242822What this trial is testingEvaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene AlterationsWho this might be right forSolid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma Kinnate Biopharma 54
Testing effectiveness (Phase 2)Study completedNCT05253807What this trial is testingStudy to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Incyte Corporation 8
Early research (Phase 1)Study completedNCT05241834What this trial is testingLOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentWho this might be right forCarcinoma, Non-Small-Cell LungThyroid Neoplasms Eli Lilly and Company 70
Testing effectiveness (Phase 2)Ended earlyNCT02109016What this trial is testingAssess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsWho this might be right forNon-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLC+6 more Clovis Oncology, Inc. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05020912What this trial is testingAlteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic TherapyWho this might be right forBasal Cell Carcinoma Case Comprehensive Cancer Center 18